Cost-Effectiveness Analysis for the Treatment of Diabetic Foot Ulcer in France: Platelet-Rich Plasma vs Standard of Care

References

• Rayner R, Carville K, Keaton J, et al. Leg ulcers: atypical presentations and associated co-morbidities. Wound Pract Res. 2009;17(4):168–185.
   Google Scholar
• Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013;Article ID 413604:9.
   Google Scholar
• Greer N, Foman N, Dorrian J, et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. VAESP Project #09-009; 2012.
   Google Scholar
• Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community – based patient cohort. Diabet Med. 2002;19:377–384. doi:10.1046/j.1464-5491.2002.00698.x
   PubMed Web of Science ®Google Scholar
• Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21:1071. doi:10.2337/diacare.21.7.1071
   PubMed Web of Science ®Google Scholar
• Siersma V, Thorsen H, Holstein PE, et al. Importance of factors determining the low health-related quality of life in people presenting with a diabetic foot ulcer: the Eurodiale study. Diabet Med. 2013;30:1382. doi:10.1111/dme.12254
   PubMed Web of Science ®Google Scholar
• Hopkins RB, Burke N, Harlock J, et al. Economic burden of illness associated with diabetic foot ulcers in Canada. BMC Health Serv Res. 2015;15:13. doi:10.1186/s12913-015-0687-5
   PubMed Web of Science ®Google Scholar
• Buckley CM, O’Farrell A, Canavan RJ, et al. Trends in the incidence of lower extremity amputations in people with and without diabetes over a five-year period in the Republic of Ireland. PLoS One. 2012;7:e41492. doi:10.1371/journal.pone.0041492
   PubMed Web of Science ®Google Scholar
• Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117:1219–1222. doi:10.1172/JCI32169
   PubMed Web of Science ®Google Scholar
• Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia. 2008;51:1826–1834. doi:10.1007/s00125-008-1089-6
   PubMed Web of Science ®Google Scholar
• Guest JF, Fuller GW, Vowden P. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018;15(1):43–52. doi:10.1111/iwj.12816
   PubMed Web of Science ®Google Scholar
• Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–228. doi:10.1001/jama.293.2.217
   PubMed Web of Science ®Google Scholar
• Hicks CW, Selvarajah S, Mathioudakis N, et al. Burden of infected diabetic foot ulcers on hospital admissions and costs. Ann Vasc Surg. 2016;33:149–158. doi:10.1016/j.avsg.2015.11.025
   PubMed Web of Science ®Google Scholar
• Anderson I. Aetiology, assessment and management of leg ulcers. Wound Essent. 2006;1:20–36.
   Google Scholar
• Winkley K, Stahl D, Chalder T, Edmonds ME, Ismail K. Risk factors associated with adverse outcomes in a population based prospective cohort study of people with their first diabetic foot ulcer. J Diabetes Complications. 2007;21:341–349. doi:10.1016/j.jdiacomp.2007.09.004
   PubMed Web of Science ®Google Scholar
• Pound N, Chipchase S, Treece K, Game F, Jeffcoate W. Ulcer-free survival following management of foot ulcers in diabetes. Diabet Med. 2005;22:1306–1309. doi:10.1111/j.1464-5491.2005.01640.x
   PubMed Web of Science ®Google Scholar
• Peters EJG, Armstrong DG, Lavery LA. Risk factors for recurrent diabetic foot ulcers: site matters. Diabetes Care. 2007;30:2077–2079. doi:10.2337/dc07-0445
   PubMed Web of Science ®Google Scholar
• Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491–494. doi:10.2337/diacare.26.2.491
   PubMed Web of Science ®Google Scholar
• Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet rich plasma for treating chronic wounds. Cochrane Database Syst Rev. 2012;10:Art. No.: CD006899. doi:10.1002/14651858.CD006899.pub2
   PubMed Web of Science ®Google Scholar
• Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J. 2011;8(3):307–312. doi:10.1111/j.1742-481X.2011.00797.x
   PubMed Web of Science ®Google Scholar
• O’Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. 2001;88:4–21. doi:10.1046/j.1365-2168.2001.01631.x
   PubMed Web of Science ®Google Scholar
• Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg. 2001;27:347–351. doi:10.1046/j.1524-4725.2001.00280.x
   PubMed Web of Science ®Google Scholar
• Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. J Biomed Sci. 2017;24:16. doi:10.1186/s12929-017-0324-1
   PubMed Web of Science ®Google Scholar
• Senet P, Bon FX, Benbunan M, et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg. 2003;38:1342–1348. doi:10.1016/S0741-5214(03)00908-X
   PubMed Web of Science ®Google Scholar
• Picard F, Hersant B, Bosc R, Meningaud JP. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: a review and a proposal for a new standard care. Wound Repair Regen. 2015;23(5):638–643. doi:10.1111/wrr.12317
   PubMed Web of Science ®Google Scholar
• Conde-Montero E, de la Cueva Dobao P, Martínez González JM. Platelet-rich plasma for the treatment of chronic wounds: evidence to date. Chronic Wound Care Manag Res. 2017;4:107–120. doi:10.2147/CWCMR.S118655
   Web of Science ®Google Scholar
• Hirase T, Ruff E, Surani S, Ratnani I. Topical application of platelet-rich plasma for diabetic foot ulcers: a systematic review. World J Diabetes. 2018;9(10):172–179. doi:10.4239/wjd.v9.i10.172
   PubMed Web of Science ®Google Scholar
• Del Pino-Sedeño T, Trujillo-Martín MM, Andia I, et al. Platelet-rich plasma for the treatment of diabetic foot ulcers: a meta-analysis. Wound Repair Regen. 2019;27(2):170–182. doi:10.1111/wrr.12690
   PubMed Web of Science ®Google Scholar
• Hsieh TS, Chiu WK, Yang TF, Wang HJ, Chen C. A meta-analysis of the evidence for assisted therapy with platelet-rich plasma for atrophic acne scars. Aesthetic Plast Surg. 2019;43(6):1615–1623. doi:10.1007/s00266-019-01471-w
   PubMed Web of Science ®Google Scholar
• Shen Z, Zheng S, Chen G, et al. Efficacy and safety of platelet-rich plasma in treating cutaneous ulceration: a meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2019;18(2):495–507. doi:10.1111/jocd.12853
   PubMed Web of Science ®Google Scholar
• Ding H, Fu XL, Miao WW, Mao XC, Zhan MQ, Chen HL. Efficacy of autologous platelet-rich gel for diabetic foot wound healing: a meta-analysis of 15 randomized controlled trials. Adv Wound Care (New Rochelle). 2019;8(5):195–207. doi:10.1089/wound.2018.0861
   PubMed Web of Science ®Google Scholar
• Li Y, Gao Y, Gao Y, et al. Autologous platelet-rich gel treatment for diabetic chronic cutaneous ulcers: a meta-analysis of randomized controlled trials. J Diabetes. 2019;11(5):359–369. doi:10.1111/1753-0407.12850
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhao J, Xie J, Lv Y, Cao DS. The efficacy of platelet-rich plasma dressing for chronic nonhealing ulcers: a meta-analysis of 15 randomized controlled trials. Plast Reconstr Surg. 2019;144(6):1463–1474. doi:10.1097/PRS.0000000000006281
   PubMed Web of Science ®Google Scholar
• Hu Z, Qu S, Zhang J, et al. Efficacy and safety of platelet-rich plasma for patients with diabetic ulcers: a systematic review and meta-analysis. Adv Wound Care (New Rochelle). 2019;8(7):298–308. doi:10.1089/wound.2018.0842
   PubMed Web of Science ®Google Scholar
• Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008;21(12):568–575. doi:10.1097/01.ASW.0000323589.27605.71
   PubMedGoogle Scholar
• Cobos Campos R, Parraza Diez N, Aizpuru Barandiaran F. Platelet-rich plasma in skin ulcer treatment. Wounds. 2013;25(9):256–262.
   PubMed Web of Science ®Google Scholar
• Linertová R, Del Pino-Sedeño T, Pérez LG, et al. Cost-effectiveness of platelet-rich plasma for diabetic foot ulcer in Spain [published online ahead of print, 2020 Feb 10]. Int J Low Extrem Wounds. 2020;1534734620903239. doi:10.1177/1534734620903239.
   Web of Science ®Google Scholar
• Clavel S, Albache N, Labrut H, Robu E, Denizot C. Autologous platelet gel: an help in chronic deep diabetic foot ulcers treatment in “2019 Diabetic Foot Conference Abstracts”. J Diabetes Sci Technol. 2020;14(3):601–678. doi:10.1177/1932296819897643
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. doi:10.1016/j.jval.2012.02.008
   PubMed Web of Science ®Google Scholar
• Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJV. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30:549–556. doi:10.1016/S1262-3636(07)70154-4
   PubMed Web of Science ®Google Scholar
• Tchero H, Kangambega P, Lin L, et al. Cost of diabetic foot in France, Spain, Italy, Germany and United Kingdom: a systematic review. Ann Endocrinol (Paris). 2018;79(2):67–74. doi:10.1016/j.ando.2017.11.005
   PubMed Web of Science ®Google Scholar
• Barshes NR, Belkin M; MOVIE Study Collaborators. A framework for the evaluation of “value” and cost-effectiveness in the management of critical limb ischemia. J Am Coll Surg. 2011;213(4):552–66.e5. doi:10.1016/j.jamcollsurg.2011.07.011
   PubMed Web of Science ®Google Scholar
• Dubský M, Jirkovská A, Bem R, et al. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. Int Wound J. 2013;10(5):555–561. doi:10.1111/j.1742-481X.2012.01022.x
   PubMed Web of Science ®Google Scholar
• Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290–308. doi:10.1177/027298902400448867
   PubMed Web of Science ®Google Scholar